Maxim Group Reiterates $5 Price Target on Mast Therapeutics (MSTX)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/31/2026
- Take-Two stock drops as GTA 6 leaks continue
- GameStop posts higher income despite revenue drop in Q2 2026
- At least eight die, 18 missing after ferry capsizes off North Cyprus
- PG&E downgraded by Wells Fargo, BMO as California wildfire reform falls short
- Wall St dips as rising oil prices, hawkish Fed bets pressure stocks
Mast Therapeutics Provides Business Update
January 7, 2016 8:01 AM ESTSAN DIEGO, Jan. 7, 2016 /PRNewswire/ --Â Mast Therapeutics, Inc. (NYSE MKT: MSTX), a biopharmaceutical company developing novel, clinical-stage therapies for sickle cell disease and heart failure today provided a business update.
The Company reported that patient enrollment in the pivotal Phase 3 "EPIC" study of its lead product candidate, vepoloxamer (MST-188), in sickle cell disease recently surpassed the 90% mark. The Company expects to... More